Please login to the form below

Not currently logged in

Gilead completes acquisition of MiroBio in $405m cash deal


The UK biotech is a spin-out of Oxford University focused on research into autoimmune diseases

Novo Nordisk to acquire Forma Therapeutics in deal worth $1.1bn

The acquisition will focus on expanding the company’s blood disorders portfolio

Novartis to separate generic drugs division Sandoz to create standalone company

Novartis buildingThe spin-off will allow shareholders to participate fully in the potential future upside of both companies

Merck and Orna agree on deal worth $3.5bn for RNA technology

Merck & Co HQThe companies will work together to develop proprietary circular RNA technology

Bristol Myers Squibb successfully completes acquisition of Turning Point Therapeutics

BMS buildingThe deal offers BMS a pipeline of investigational medicines to expand its oncology portfolio, including repotrectinib

Bristol Myers Squibb and GentiBio in $1.9bn deal to develop IBD therapies

BMS buildingThe companies will work together to develop new therapies to re-establish immune tolerance and repair tissue for those with inflammatory bowel diseases

Merck and Cerevance to research novel targets in Alzheimer’s disease

Merck & Co HQThe total value of the deal is expected to be around $1.1bn

Pfizer set to acquire Global Blood Therapeutics in deal worth $5.4bn

Pfizer NY headquartersThe acquisition will help accelerate research into sickle cell disease

AbbVie and Sosei Heptares collaborate in new agreement worth up to $1.2bn

AbbVieThe agreement will focus on drug discovery, development and commercialisation of neurological diseases

Business in the USAHealth coverage across state lines

Despite a total lack of legislative wins, the new administration has made its presence felt at home and abroad

  • Ho_Ung_KimStanding out in a crowd

    Celltrion Healthcare’s Ho-Ung Kim on pricing, market access and regulatory challenges for successfully developing biosimilars

  • HeadsThe diseased organisation

    Like humans, organisations can be afflicted by genetic disorders that hinder performance and threaten survival but these can be understood and cured

Subscribe to our email news alerts

Featured jobs


Add my company

KVA is an award winning full-service digital communications & brand experience agency. Our healthcare expertise blends creative ‘outside-the-box’ thinking with...

Latest intelligence

Neil Thompson
How AI is finally helping rare diseases gain more than just attention
By Neil Thompson...
Is communication failing us?
Compelling people to care in a world oversaturated with news and information...
Are your field teams ready to excel in the new era?
A qualitative research approach to help you critically assess post-pandemic learnings and ignite the potential of meaningful interactions with HCPs....